Treats relapsing forms of multiple sclerosis (MS). ANDA 210538, held by Zydus Pharms. Dimethyl Fumarate.
As of Nov 16, 2026, ANDA 210538 (Dimethyl Fumarate), held by Zydus Pharms, was first approved by FDA on Sep 24, 2020, with 0 approved supplements and 0 published complete response letters.
Dimethyl fumarate is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 24, 2020 | Original application | Approved | None posted |
| Dimethyl Fumarate120MG · capsule, delayed release;oral | Dimethyl Fumarate | Discontinued |
| Dimethyl Fumarate240MG · capsule, delayed release;oral | Dimethyl Fumarate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters